Stock Scorecard
Stock Summary for Orchestra BioMed Holdings Inc (OBIO) - $4.77 as of 12/3/2025 12:08:00 PM EST
Total Score
7 out of 30
Safety Score
21 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for OBIO
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for OBIO
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for OBIO
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for OBIO
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for OBIO (21 out of 100)
| Stock Price Rating (Max of 10) | 3 |
| Historical Stock Price Rating (Max of 10) | 5 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 3 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 4 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for OBIO
Financial Details for OBIO
Company Overview |
|
|---|---|
| Ticker | OBIO |
| Company Name | Orchestra BioMed Holdings Inc |
| Country | USA |
| Description | Orchestra BioMed Holdings, Inc. (OBIO) is an innovative therapeutic device company headquartered in New Hope, Pennsylvania, focused on transforming treatment paradigms for cardiovascular diseases through its cutting-edge product offerings. Leveraging proprietary technologies, OBIO addresses critical unmet clinical needs, enhancing patient outcomes and revolutionizing therapeutic strategies in cardiology. With a robust commitment to advancing healthcare access and quality, Orchestra BioMed is well-positioned as an emerging leader in the medical device sector, promising significant contributions to the future of cardiovascular care. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 4.77 |
| Price 4 Years Ago | 10.08 |
| Last Day Price Updated | 12/3/2025 12:08:00 PM EST |
| Last Day Volume | 109,750 |
| Average Daily Volume | 334,484 |
| 52-Week High | 6.30 |
| 52-Week Low | 2.20 |
| Last Price to 52 Week Low | 116.82% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 43.11 |
| Sector PE | 88.06 |
| 5-Year Average PE | -99.46 |
| Free Cash Flow Ratio | 6.45 |
| Industry Free Cash Flow Ratio | 13.81 |
| Sector Free Cash Flow Ratio | 28.78 |
| Current Ratio Most Recent Quarter | 4.73 |
| Total Cash Per Share | 0.74 |
| Book Value Per Share Most Recent Quarter | 0.78 |
| Price to Book Ratio | 6.87 |
| Industry Price to Book Ratio | 33.69 |
| Sector Price to Book Ratio | 33.12 |
| Price to Sales Ratio Twelve Trailing Months | 99.99 |
| Industry Price to Sales Ratio Twelve Trailing Months | 31.75 |
| Sector Price to Sales Ratio Twelve Trailing Months | 15.97 |
| Analyst Buy Ratings | 3 |
| Analyst Strong Buy Ratings | 3 |
Share Statistics |
|
| Total Shares Outstanding | 56,465,000 |
| Market Capitalization | 269,338,050 |
| Institutional Ownership | 40.67% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -24.23% |
| Reported EPS 12 Trailing Months | -1.80 |
| Reported EPS Past Year | -1.39 |
| Reported EPS Prior Year | -1.66 |
| Net Income Twelve Trailing Months | -75,101,000 |
| Net Income Past Year | -61,024,000 |
| Net Income Prior Year | -49,120,000 |
| Quarterly Revenue Growth YOY | -12.80% |
| 5-Year Revenue Growth | -17.53% |
| Operating Margin Twelve Trailing Months | -2,359.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 42,012,000 |
| Total Cash Past Year | 22,261,000 |
| Total Cash Prior Year | 30,559,000 |
| Net Cash Position Most Recent Quarter | 27,808,000 |
| Net Cash Position Past Year | 7,969,000 |
| Long Term Debt Past Year | 14,292,000 |
| Long Term Debt Prior Year | 9,490,000 |
| Total Debt Most Recent Quarter | 14,204,000 |
| Equity to Debt Ratio Past Year | 0.70 |
| Equity to Debt Ratio Most Recent Quarter | 0.75 |
| Total Stockholder Equity Past Year | 32,958,000 |
| Total Stockholder Equity Prior Year | 68,043,000 |
| Total Stockholder Equity Most Recent Quarter | 43,739,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -60,793,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -1.08 |
| Free Cash Flow Past Year | -50,847,000 |
| Free Cash Flow Prior Year | -46,205,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | None |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.42 |
| MACD Signal | 0.33 |
| 20-Day Bollinger Lower Band | 1.56 |
| 20-Day Bollinger Middle Band | 3.30 |
| 20-Day Bollinger Upper Band | 5.05 |
| Beta | 0.65 |
| RSI | 70.50 |
| 50-Day SMA | 3.64 |
| 150-Day SMA | 6.59 |
| 200-Day SMA | 7.42 |
System |
|
| Modified | 12/2/2025 5:35:33 AM EST |